Product Code: ETC8846614 | Publication Date: Sep 2024 | Updated Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The market for neurological disorder drugs is growing with increased investment in novel therapeutics, biosimilars, and personalized medicine approaches. Improved access to treatments is benefiting patients with chronic neurological conditions.
The growing prevalence of neurological disorders, including epilepsy, Parkinsons disease, and Alzheimers, is driving the neurological disorder drugs market in the Philippines. Increased awareness and diagnosis rates, along with an aging population, are contributing to rising demand for effective medications. Advances in drug development, including novel therapeutics targeting neurodegenerative diseases, are expanding treatment options. Government initiatives aimed at improving access to essential medicines and expanding healthcare coverage are further supporting market growth.
The market for neurological disorder drugs in the Philippines is driven by the rising prevalence of conditions such as epilepsy, migraines, and neurodegenerative diseases. Pharmaceutical companies are investing in new drug formulations and improved treatment options. However, the market faces challenges such as high drug costs, limited reimbursement policies, and long approval processes for new medications. Moreover, patient adherence to neurological treatments remains a concern due to side effects and accessibility issues. Despite these hurdles, increasing government initiatives for healthcare improvement and expanding pharmaceutical research support market growth.
The increasing burden of neurological disorders such as epilepsy, schizophrenia, and migraine in the Philippines has created investment opportunities in neurological disorder drugs. Investors can focus on drug repurposing, novel therapeutic formulations, and biologic treatments. With government initiatives supporting healthcare expansion, companies in this space can secure regulatory approvals and market entry more effectively.
The regulation of neurological disorder drugs ensures their safety, efficacy, and affordability for patients. Government policies promote the inclusion of these drugs in the national health insurance program to improve accessibility. The DOH negotiates with pharmaceutical companies to lower medication costs and supports clinical trials for emerging treatments in neurological care.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Neurological Disorder Drugs Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Neurological Disorder Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Neurological Disorder Drugs Market - Industry Life Cycle |
3.4 Philippines Neurological Disorder Drugs Market - Porter's Five Forces |
3.5 Philippines Neurological Disorder Drugs Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Philippines Neurological Disorder Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.7 Philippines Neurological Disorder Drugs Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Philippines Neurological Disorder Drugs Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 Philippines Neurological Disorder Drugs Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Philippines Neurological Disorder Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Philippines Neurological Disorder Drugs Market Trends |
6 Philippines Neurological Disorder Drugs Market, By Types |
6.1 Philippines Neurological Disorder Drugs Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Epilepsy, 2021- 2031F |
6.1.4 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Alzheimers Disease, 2021- 2031F |
6.1.5 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Parkinsons Disease, 2021- 2031F |
6.1.6 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Multiple Sclerosis, 2021- 2031F |
6.1.7 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Cerebrovascular Disease, 2021- 2031F |
6.1.8 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Philippines Neurological Disorder Drugs Market, By Drug Class |
6.2.1 Overview and Analysis |
6.2.2 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Cholinesterase Inhibitors, 2021- 2031F |
6.2.3 Philippines Neurological Disorder Drugs Market Revenues & Volume, By NMDA Receptor Antagonists, 2021- 2031F |
6.2.4 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Antiepileptic, 2021- 2031F |
6.2.5 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Antipsychotic and Antidepressant, 2021- 2031F |
6.2.6 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Philippines Neurological Disorder Drugs Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.3.4 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Philippines Neurological Disorder Drugs Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.4.4 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.5 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Philippines Neurological Disorder Drugs Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.5.4 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.5 Philippines Neurological Disorder Drugs Market Revenues & Volume, By Others, 2021- 2031F |
7 Philippines Neurological Disorder Drugs Market Import-Export Trade Statistics |
7.1 Philippines Neurological Disorder Drugs Market Export to Major Countries |
7.2 Philippines Neurological Disorder Drugs Market Imports from Major Countries |
8 Philippines Neurological Disorder Drugs Market Key Performance Indicators |
9 Philippines Neurological Disorder Drugs Market - Opportunity Assessment |
9.1 Philippines Neurological Disorder Drugs Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Philippines Neurological Disorder Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.3 Philippines Neurological Disorder Drugs Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Philippines Neurological Disorder Drugs Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 Philippines Neurological Disorder Drugs Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Philippines Neurological Disorder Drugs Market - Competitive Landscape |
10.1 Philippines Neurological Disorder Drugs Market Revenue Share, By Companies, 2024 |
10.2 Philippines Neurological Disorder Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |